pancreatic ductal adenocarcinoma

Targeting NSUN6 Deficiency to Overcome Immune Suppression in Pancreatic Cancer: Insights into the KDM5A-CCL2-Macrophage Axis

By MedXY 08/21/2026

NSUN6 deficiency in pancreatic cancer promotes immune suppression by enhancing immunosuppressive macrophage infiltration via the KDM5A-CCL2 axis, leading to resistance to immune checkpoint blockade; targeting this pathway offers a promising therapeutic approach.

Gastroenterology news Oncology

Targeting SMPD1-Driven Sphingolipid Metabolism to Disrupt KRAS Signaling in Pancreatic Ductal Adenocarcinoma

By MedXY 07/08/2026

This study reveals that dysregulated sphingolipid metabolism via SMPD1 supports KRAS-driven pancreatic cancer progression, identifying SMPD1 as a promising therapeutic target in pancreatic ductal adenocarcinoma.

AI Gastroenterology news

AI Radiomics Detects Visually Occult Pancreatic Cancer on CT Nearly 16 Months Before Diagnosis and Outperforms Radiologists

By MedXY 05/04/2026

A multi-institutional AI model identified pre-diagnostic pancreatic cancer on routine CT with meaningful lead time, higher sensitivity than radiologists, longitudinal stability, and externally validated specificity in a low-prevalence setting.